Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemo fog inside the belly: could PIPAC boost ovarian cancer surgery success?

NCT ID NCT07514494

Disease control Sponsor: Moscow Regional Oncological Dispensary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if giving chemotherapy as a pressurized mist directly into the abdomen (PIPAC) alongside standard IV chemo can help more women with advanced ovarian cancer have successful tumor-removal surgery. It includes 160 women aged 18-75 with stage IIIB-IIIC disease. The goal is to see if this approach improves surgery outcomes and extends survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female, age 18-75 years. * Histologically verified ovarian cancer with peritoneal carcinomatosis. * FIGO stage IIIB or IIIC. * visually detectable peritoneal carcinomatosis. * Peritoneal metastatic involvement documented preoperatively by ultrasound, CT, MRI, PET-CT, or equivalent imaging. * Ability to comply with protocol procedures and provide written informed consent. Exclusion Criteria: * Age \> 75 years; ECOG 3-4; cachexia with BMI \<= 16. * Severe concomitant disease in exacerbation or decompensation. * Extra-abdominal metastases, including metastatic pleuritis. * Mucinous ovarian carcinoma or another active malignant neoplasm, except malignancies in clinical remission for more than 2 years. * Pronounced adhesive disease of the abdominal cavity. * Pregnancy or breastfeeding. * Positive BRCA1 or BRCA2 status. * Any condition precluding safe PIPAC or protocol execution, including hollow-organ perforation, gastrointestinal resection with anastomosis, or repair of a hollow-viscus defect. * Refusal of treatment at any study stage.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced epithelial ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian carcinoma peritoneal carcinomatosis peritoneal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced epithelial ovarian cancer Peritoneal carcinomatosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Moscow Regional Oncological Dispensary

    RECRUITING

    Balashikha, 14390, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.